

Index

- A3GALT2, 143
- AAV, 360
- AAV genomes, 361
- AAV6, 305
- AAVS1, 309
- abnormal eye, 79
- ACTB, 60
- ADA-SCID, 310, 446
- adeno-associated-based vectors, 339
- adeno-associated vectors, 227
- adeno-associated virus (AAV), 274
- adenocarcinoma, 327
- Agencourt AMPure XP beads, 346
- AGIL, 377
- Agilent bioanalyzer, 28
- AIDS, 305, 406
- ALB, 145
- allograft rejection, 405
- allo-HSCT, 301
- allotetraploid, 84
- alternative end joining (AEJ), 13
- Alzheimer disease (AD), 141, 257, 373
- Amara Nucleofector 2b device, 154
- aminomethyltroxalen (AMT), 383
- amyotrophic lateral sclerosis, 141
- animal agriculture, 138
- anti-ETFA, 243
- anti-GAPDH, 243
- apical membrane, 359
- aptamers, 392
- ASFV, 139
- ASOs, 381
- assisted reproductive technology (ART), 447
- ataxia-telangiectasia, 141
- autoimmunity, 417
- bacterial artificial chromosomes (BACs), 253, 274
- Bbs I, 44
- B-cell lymphoma, 322
- BCL11A, 307
- BCP-ALL, 259
- Benchling, 240
- bGH, 56, 57
- biallelic knockin, 159
- biallelic mutated clones, 57
- bile ducts, 290
- biliary epithelial cells, 290, 292
- Bim* and *Mcl-1*, 322
- biopsies, 113
- biotinylated, 28
- biotinylated probes, 60
- bipartite, 55
- BLESS, 33
- B-lymphoid malignancies, 257
- bone marrow stromal, 125
- bovine serum, 25
- bradykinesia, 141
- BRAF1, 54
- Braveheart (*Bvht*), 375
- Burkitt's lymphoma, 322
- Burrows–Wheeler algorithm, 48
- C. briggsae*, 7
- C. elegans*, 3
- canals of Hering, 289
- cancer, 315
- cancer modeling, 316
- cancer mutations, 337
- carcinogenesis, 332
- cardiovascular epithelia, 330
- CARMEN, 375
- cartilage-hair hypoplasia (CHH), 417
- Cas9, 9, 176, 317, 441
- Cas9 cleavage, 12
- Cas9 mRNA, 166
- Cas9 protein, 87, 276
- Cas9/RNP, 13
- Cas9/sgRNA cells, 105
- Cas9-DNA, 102
- Cas9-microinjected worms, 12
- Cas9RNP, 404
- CCNA2, 60

Index	465
CCR5, 305, 392	CRISPR genome editing, 169
CCR5 knockdown, 394	CRISPR mutagenesis, 167
CD163, 140	CRISPR RNA, 337
CD34 ⁺ cell, 301	CRISPR systems, 318
CD4 ⁺ T cells, 305	CRISPR technology, 97, 231, 433
CD49f, 303	CRISPR/Cas9, 25, 40, 150, 402
cDNA, 44, 46, 307	CRISPR/Cas9 mutagenesis, 91
CEL-I endonuclease, 184	CRISPR/Cas9 reagents, 44
cell signaling, 44	CRISPR/Cas9 system, 144
cell therapy, 280	CRISPR-associated (Cas) proteins, 8
CEP290, 365	CRISPR-based cancer modeling, 317
ceRNAs, 53, 54, 61, 63	CRISPR-based therapeutics, 361
cervical cancer, 447	CRISPRDirect, 87
Chast, 372	CRISPR-GA, 186
ChemiDoc-It2 (UVP), 243	CRISPRi, 59, 198
Cheminpharma, 343	CRISPRScan, 87
chemokines, 101, 111, 305	crRNA, 8, 72
chemotherapeutic modulators, 408	crustacean, 71
chimeric ZFN, 55	CS domain, 59
chorionic gonadotropin, 87	C-terminus, 77
chromatin, 12	cultured cell lines, 44
chromatograms, 170	custom-designed artificial nucleases,
chromosome conformation capture (3 C),	71
202	CXCR4, 307
ciliary trafficking, 365	CYP4Z2P, 54
ciliogenesis, 365	CypD, 340
cinobufagin metabolism, 124	Cys2His2 zinc fingers, 133
CLASH, 46	cytidine deaminase, 34
classical non-homologous end joining	cytokine IL8, 415
(C-NHEJ), 182	cytokines, 111
cleavage domain, 135	cytomegalovirus (CMV), 26
CLIS, 25, 30, 31	cytoplasm, 53
CLIS analysis, 29	cytoplasmic protein, 142
clonal isolation, 44	cytoplasts, 117
cloning, 245	cytotoxic effects, 59
CLP, 301	cytotoxic T lymphocytes (CTLs), 397
clustered regularly interspaced short	cytotoxicity, 71
palindromic repeat (CRISPR), 23	
CMAH, 143	<i>D. magna</i> , 71, 76
cNHEJ, 167	<i>D. magna</i> histone H2B, 74
co-CRISPR, 12	<i>D. melanogaster</i> , 11
codon-swap mutation, 158	<i>D. pulex</i> , 71
common myeloid (CMP), 301	<i>D. rerio</i> , 11
conditional knockout (CKO), 107	D10A, 34
conventional gene targeting, 272	D10ACas9 nickase, 123
Costantini, 316	<i>Daphnia</i> , 71, 76, 82
Cpf1, 176, 441	<i>Daphnia magna</i> , 72
Cre or doxycycline-inducible transgenes,	DBD, 55
318	dCas9, 34, 59, 61, 332
Cre recombinase, 125, 351	dCas-VPR, 398
Cre/Lox, 316	dChIRP, 382
Cre-ERT2, 342	DD-Cas9 vector, 349
Cre-Lox methods, 327	DD-GFP, 340
Cre-Lox system, 342, 352	dendritic cells (DCs), 404
Cre-recombinase of LoxP sites, 377	densitometry, 26
CRISP-Disp, 61	DGGE, 183
CRISPR, 12, 30, 32, 34, 40, 46, 48, 53, 55, 61,	diabetes, 373
71, 165, 376	diagnostic RFLP, 158
CRISP-R, 186	Dicer endonuclease, 53
CRISPR design tool, 98	Dickinson, 103

466 **Index**

- digenome, 33
- diploid, 84
- Dma-ey*, 72
- Dma-ey* locus, 76
- Dma-ey* RNAi, 74
- Dma-ey*-deficient daphniids, 75
- Dmavas*, 76
- DMEM, 25, 243
- DNA-binding motifs, 275
- Dolly the sheep, 110
- donor plasmid, 73
- donor plasmid DNA, 79
- dosing, 297
- double-stranded DNA, 14
- double-stranded DNA break (DSB), 271
- Doudna and Sontheimer, 337
- doxycycline-inducible promoters, 339
- doxycycline-inducible systems, 330
- Drosophila*, 40, 48, 72
- Drosophila* flies, 75
- DSBs, 22, 55, 40, 97, 121
- dsDNA, 59, 304
- DSG, 383
- dsODNs, 33
- DsRed2-double fluorescence, 158
- dual sgRNAs, 106
- dysferlin (DYSF), 255

- E490K, 73
- ECB, 257
- EGFP, 137
- EGFR, 340, 344
- ELD/KKR mutations, 76
- electrophoresis, 7
- electroporation, 254
- elongation factor-1 α short (EFS), 342
- embryogenesis, 85
- embryonic stem (ES) cells, 165, 253
- embryos, 90
- EMC, 184
- EML4-ALK*, 339
- enChIP, 195
- enChIP-RNA-Seq, 202
- endogenous retroviruses, 144
- endonucleases, 22, 41, 110, 166
- engraftment, 86
- EP patent, 428
- episomal, 25
- ES, 338
- esiRNA, 54
- ESTs, 71
- ETFA*, 240
- ethyl methane sulfonate (EMS), 3
- eukaryotes, 275
- eukaryotic Cys2-His2 zinc-finger, 22
- European patent, 437
- exenatide, 125
- exogenous factors, 44

- exon7, 75
- exon9, 75
- exon X, 365
- expectation maximization (EM) algorithm, 229
- extracellular matrix (ECM)., 289
- ey1-TALEN, 75, 79
- ey1-TALEN-left, 73
- ey1-TALEN-right, 73
- ey1-TALENs, 78
- ey2-TALEN, 75, 79

- F0 CRISPR/Cas9 analysis, 92
- F0 phenotypic analyses, 84
- F1 progeny, 95
- FA-C gene, 255
- facile genome, 39
- FACS, 105
- FACS parameters, 155
- FACS-based editing, 159
- FAH (fumarylacetoacetate hydrolase), 255
- Fanconi anaemia type C, 255
- Feng Zhang, 98
- fertilization, 87
- fibroblasts, 360
- fibrogenic stellate, 292
- Fire and Mello, 54
- FISH, 60
- FKBP12 protein, 340
- fluorescent juveniles, 80
- fluorescent protein (FP), 151
- FokI nuclease, 34
- FokI, 5
- FokI domain, 75
- FokI endonuclease, 55, 121
- FokI nuclease, 58
- formaldehyde, 347
- FRET, 63

- G0 adults, 76
- G0 eggs, 76
- G0 juveniles, 76
- G0-resting phase, 117
- G1 juveniles, 76
- G1 progeny, 76
- Gabriel, 25
- galactosyltransferase, 110
- GAPDH mRNA, 60
- gDNA, 23, 44, 46
- GEMMs, 338
- Gendicine, 446
- gene expression, 44
- gene therapeutics, 286
- gene therapy, 254, 359
- gene therapy trials, 454
- gene-of-interest (GOI), 114, 250
- GenERA, 46
- genetic engineering, 246, 329
- genetic modification, 455

Index	467
genome editing, 132, 270, 279, 360, 447 genome editing technologies, 434 genomic DNA, 46, 74, 344 genomic fragment, 25 genomic safe harbor (GSH), 448 genomic screening., 339 genotyping, 74, 76 germline cells, 446 germline modification, 319 germline mutagenesis, 261 GFP, 56, 57, 60, 158 GFP fluorescence level, 155 GFP protein, 74 GFP transgene, 170 GFP-positive cells, 105 GG dinucleotide, 11 glutamine, 25 glycoprotein, 26 Golden Gate approach, 73 Gonzalez, 97 <i>gp91phox</i> , 309 gRNA, 41, 72, 145, 225, 360 gRNA1, 75 gRNA2, 75 gRNA-blocking mutations, 154 gRNAs, 75 GUIDE, 33 GVHD, 301 GWAS, 375 gyrencephalic, 111 H2B-GFP, 74, 79 H3K4me3, 415 H537K, 73 haemophilia B, sickle cell disease, 255 handmade cloning, 110 hCRP, 144 HCT116 cells, 243 HDAdVs, 274 HDR, 40, 44, 169, 281, 317 HDR efficiency, 102, 172 HDR oligos, 46 HDR repair, 239 HEK293 cells, 106, 187 HEK293 T, 25, 26, 29, 32, 46, 60 HeLa cell lysate, 60 hematopoiesis, 301 hemoglobinopathies, 308 hepatocyte acinar plates, 290 hepatocyte function, 289 hepatocyte streaming, 291 hepatocytes, 279, 288, 290 heritable mutagenesis, 79 hermaphrodites, 9 herpesvirus, 255 heterodimeric, 77 heterodimeric ey2-TALEN expression vectors, 73 heterodimeric TALENs, 76	heterodimerization, 71 heteroduplex DNA, 25 heterozygosity analysis, 186 heterozygotes, 7, 93 HgbS, 306 histiocytic sarcoma, 259 HIV, 305 HIV1, 406 HIV1 LTR, 397 HMC, 117 <i>HMGA1</i> , 274 HNH domain, 166 homeobox domain, 75 homodimeric ey1-TALEN expression vectors, 73 homodimeric ey2-TALEN, 73 homodimeric TALEN, 73 homology arm, 101, 103, 154 homologous recombination (HR), 55, 58 homologous sequence, 40 homology-directed repair (HDR), 13, 122 homozygous clones, 379 homozygous indels, 105 homozygous integrations, 245 HOTAIR, 54 Hotstar Taq DNA, 26 HOTTIP, 61 HPRT, 274 hPSCs, 281 HR, 145, 271, 303 HRMA, 184 HRP-conjugated antibody, 244 HSC transplantation, 285 HSCs, 296 HSCT, 257 HSPCs, 257, 301, 303 HT1080, 25, 26 HTGTS, 33 HTS, 279 HULC, 54 human cancer, 316 human embryo, 455 human embryonic stem cells (hESCs), 270, 455 human-induced pluripotent stem cells (hiPSCs), 270 human pluripotent stem cells (hPSCs), 270 humanized models, 279 Huntington's disease, 141 hybridoma cells, 404 hydrodynamic tail injection, 339 hydro-dynamic tail vein injection, 329 hygromycin, 241 hyper- or hypo-alleles, 97 I499 L, 73 I538 K, 73 iChIP technology, 195

468 **Index**

- IDAA, 155, 186
- IDLV, 24, 26, 30, 34, 305
- IDLV production, 26
- IFN, 200
- IgM genes, 145
- IgM protein expression, 145
- IL2RG, 56, 309
- immune diseases, 416
- immunogenicity, 392
- immunoglobulin (Ig) molecule, 404
- immunostaining, 349
- immunotherapy, 257
- in vitro* enChIP, 198
- in vitro* fertilization (IVF), 87, 447
- in vivo*, 196
- in vivo* enChIP, 198
- indel formation, 26
- indels, 40
- indoleacetyl glycine, 111
- indoxyl sulfate, 111
- induced pluripotent stem cells (iPSCs), 116
- INGRID, 203
- insertional mutagenesis, 454
- insulinotropic polypeptide receptor, 124
- integration efficiency, 245
- intertwined RNA networks, 60
- intracytoplasmic sperm injection (ICSI), 136, 447
- intratracheal administration, 329
- intronic mutation, 365
- inventors, 433
- inventorship, 434
- iPSCs, 360
- IRES, 352
- IRES sequence, 352
- Jennifer Doudna, 435
- JHRE/H2B-GFP, 79
- juvenile hormone response element (JHRE), 73
- K562 cells, 154
- KAPA2 G, 243
- KBM7 cells, 228
- keratinized skin surface, 287
- knockin, 97
- knockin editing, 155
- knockin frequency, 154
- knockin models, 316
- Kox1, 59
- KRAB domain, 59
- KRAS locus, 155, 157
- KRASG12D, 125
- KrasG12D mutations, 339
- KRAS P1, 54
- Krüppel homolog, 73
- Krüppel homolog1, 79
- LAM-PCR, 33
- latency reversing agents (LRAs), 397
- Lavitrano, 114
- LDI, 105
- leapfrogging, 85, 93
- Leber's congenital amaurosis (LCA), 365
- LentiCRISPR V2, 349
- LentiCRISPR V2 (Addgene) backbone, 342
- lentiviral, 226
- lentiviral construct, 343
- lentiviral vectors, 24, 339, 391
- lentivirus, 115
- LEPREL2, 31
- leukemia, 446
- Lewy bodies, 142
- LexA protein, 195
- license agreements, 432
- licensing, 432
- Li-Fraumeni syndrome, 125
- LINC00887, 31
- lincRNAs, 54
- linker primers, 26
- lipid metabolism, 111
- Lipofectamine, 25
- lipoproteins, 111
- liposomal transfection, 154
- lissencephalic, 111
- liver X receptors (LXRs), 373
- lncRNA, 56, 61, 373, 382, 401
- locus-specific chromatin immunoprecipitation, 195
- LOF phenotypes, 91, 94
- long non-coding RNAs (lncRNAs), 414
- long terminal repeat (LTR), 26
- LoxP integration sites, 107
- LoxP sites, 58
- lox-stop-lox strategies, 339
- LT-HSCs, 301
- LXR-induced sequence (LeXis), 375
- M4-sucrose, 74
- macrophages, 140, 405, 417
- MAGeCK, 229
- MaGeCK-VISPR, 229
- MALAT1, 54, 56, 376
- mammalian cells, 227
- mammalian genome, 52
- mammary gland, 329
- mass spectrometry, 62
- mass spectrometry (MS), 415
- mCherry, 60
- Mecp2 expression, 361
- meganuclease, ZFN, 23
- mESCs, 272
- messenger RNA (mRNA), 255
- metazoans, 9
- Mhrt, 372
- microhomology, 171, 239
- microhomology-mediated end joining (MMEJ), 182

microinjection, 4, 11, 74, 110	NGF, 257
microparticle bombardment, 4	NGG, 41, 176
microRNAs, 52, 371	NGS, 195
microsurgery, 88	NGS data set, 190
miR-141, 57	NHEJ, 22, 25, 40, 46, 72, 97, 121, 145, 159, 271, 281, 303
miR-200 c, 57	NIES, 72
miR-CRISPR, 41	NIES clone, 72
miRNA, 37, 41, 43, 49, 54, 57, 61, 63	Nile tilapia, 261
MiSeq platform, 48	NmCas9, 363
mitochondrial donation, 446	NN for G substitute, 73
<i>Mkl1</i> , 217	NOD, 303
MLM3613, 73	NONCODE consortium, 371
mMessage mMachine T7 kit, 74	non-exclusive licenses, 435
MMEJ, 167, 169	non-restrictive linear amplification-mediated polymerase chain reaction (nrLAM-PCR), 26
MMR, 90, 227	NRas, 217
modified-GFP fluorescent protein, 349	nrLAM, 28
MOI, 227	NSCLC, 347
MOI transduction, 343	NSG, 303
molecular footprint, 251	N-terminus, 75, 342
monogenic, 364	nuclear receptor ROR γ t, 417
monomer, 158	nuclease-2A-FP construct, 159
Morton, 7	nucleosomes, 12
Mos1 transposase, 13	nucleotide, 53
MREs, 37, 40, 61	nucleotides, 11, 25, 58
mRNA, 8, 39, 52, 250, 342	nutritional tryptophan, 111
MS, 195	
MSTN knockout pigs, 141	O'Connell, 60
multiplexed targeting, 60	Odyssey Imaging System (LICOR), 347
multipotent progenitors (MPPs), 301	oligonucleotides, 39, 44, 60, 73, 102, 202, 241
murine atherosclerosis, 373	oligos, 154
mutagenesis, 7, 9, 13, 44, 48, 71, 85	oncogenic inversions, 327
mutagenized amplicons, 7	oncogenomics, 259
mutation efficiency, 76	oocyte, 117
Million Mutation Project, 3	oogenesis, 85
<i>Myc</i> , 217	ORF, 250, 376
<i>MycN</i> , 32	organ transplantation, 144
MyD88, 414	organoid, 351
<i>Myh7</i> , 372	osteosarcoma, 259
myostatin, 141	OT3-17, 31
	ownership, 432
<i>N. meningitidis</i> , 363	
N496D, 73	p65, 59
NADPH oxidase, 309	PAM, 41, 60, 166
NAG, 41	PAM detection, 106
naked DNA, 339	PAM motifs, 12
naked plasmid, 317	PAM sequence, 31
<i>Natronobacterium gregoryi</i> (NgAgo), 23	PAM site, 152
NAVI, 240	PAMmer-RNA, 60
nCas9/sgRNA, 329	PAMmers, 60
NcoI, 74	Parkinson's disease (PD), 141, 278
ncRNA, 371	patent application, 423
ncRNAs, 52, 58, 61, 401	patent ownership, 432
NEB, 344	pathogenesis, 110, 195
nematode, 3, 9	pathological cardiac hypertrophy, 372
neomycin, 137	pathophysiology, 125
neurodegenerative disorders, 141	pattern recognition receptors (PRRs), 405
next generation sequencing (NGS) technology, 4	<i>pax6</i> , 72
NgAgo protein, 176	
nGEMMs, 408	

470 **Index**

- pCDNA3.1, 241
- pC-HELP, 26
- pCMV-Cas9-2A-GFP, 155
- pCMV-G, 26
- P-compartment, 291
- PCR, 43, 80
- PCR strip tubes, 90
- PCR-based methods, 184
- pCS-Dmavas-Cas9, 73
- pCS-Dmavas-ey1-TALEN-ELD, 73
- pCS-Dmavas-ey1-TALEN-KKR, 73
- pCS-Dmavas-ey1-TALEN-KKR., 73
- pCS-Dmavas-ey1-TALEN-left, 73
- pCS-Dmavas-ey1-TALEN-right, 73
- pCS-Dmavas-ey2-TALEN-ELD, 73
- pCS-Dmavas-ey2-TALEN-KKR, 73
- PDCD4, 58
- penicillin, 25
- destabilizing peptide (DD-), 342
- peptides, 61
- periportal hepatocytes, 290
- PGC transplantation, 86, 87, 88
- phagocytic Kupffer, 292
- phenol/chloroform protocol, 74
- phenotypes, 24
- pHIV7/pgk-puro, 26
- phosphoglycerate kinase (pgk), 26
- photoreceptor, 359
- PiCh, 200
- piRNA, 52
- PITCh, 239
- planktonic crustacean, 71
- plasmid, 360
- plasmid DNA, 79
- plasmid donor, 103
- pluripotent, 277
- pluripotent stem cells, 116
- pMK backbone, 342
- PNK, 242
- Poly(A) Tailing Kit, 74
- polyethylene glycol, 26
- polymerase, 342
- polymerase III (polIII), 10
- porcine disease, 123
- porcine endogenous retroviruses, 144
- porcine fibroblasts, 115
- preimplantation genetic diagnosis, 447
- pre-miRNAs, 53
- primary immunodeficiencies, 308
- primordial, 85
- programmable DNA, 110
- programmed death-1 (PD-1), 404
- prokaryotic, 55
- prostate adenocarcinoma, 259
- protospacer adjacent motif (PAM), 23, 72
- PRRS, 138
- PRRSV, 139
- pSPgRNA, 241
- pT3TS, 73
- pT3TS-ey2-TALEN-left, 73
- pT3TS-ey2-TALEN-right, 73
- PTGS, 390
- pulmonary, 330
- pulmonary fibrosis, 257
- PUMILIO, 384
- puromycin, 44, 48, 58, 241
- puromycin resistance (purR), 26, 29
- putative kinase1, 142
- Q486E, 73
- Q-compartment, 291
- quantitative PCR, 44
- Quick Spin RNA columns, 74
- Ras guanine nucleotide releasing protein 3 (RasGRP3), 405
- RBP, 63
- RCas9, 332
- RCas9 signal, 60
- RDE, 56
- Renilla sgRNA, 347
- repeat variable diresidue, RVD, 135
- retinal degenerations, 364
- retinal diseases, 358
- retinal dystrophies, 361
- retinal photoreceptor cells, 364
- retinal pigment epithelium (RPE), 359
- retinal therapy, 360
- retinitis pigmentosa, 364
- retroviruses, 115
- RFLP, 154, 183
- RFP, 58, 60
- RGN, 237
- rheumatoid arthritis, 416
- ribonucleoprotein (RNP), 360
- ribonucleoprotein termed RALY, 375
- RIP, 384
- Ripk1*, 217
- Ripk3*, 217
- RISC, 54, 380, 402
- Rmrp, 201
- RNA interference (RNAi), 54, 390, 402
- RNA tracking, 22
- RNA-FISH, 202
- RNA-guided, 317
- RNA-labeling, 60
- RNase III endonuclease Drosha, 53
- RNaseP, 56
- RNA-Seq, 49, 195
- RNA-tracking, 60
- RPA3, 340
- RRA, 229
- rRNA, 52
- RSK4, 158
- RuvC domain, 166
- RVD, 73
- S. pyogenes*, 237
- SACK, 296

Index

471

- Salmonella* infection, 415
 SB100X, 250
 SB100X system, 257
 scFV, 392
 SCID, 309
 SCNT, 110
 scRNA, 60
 scRNAs, 59
 scrofa RELA proto-oncogene, 140
 sgRNA, 9, 12, 24, 30, 41, 43, 55, 61, 97, 167, 245, 337
 sgRNA efficacy, 98
 sgRNA can, 34, 59, 61, 86, 318
SH2D1A, 32
 shRNAs, 54, 209, 230, 281, 402
 sickle cell disease (SCD), 306
 SIGLEC1, 140
 Sigma's CompoZr ZFN vectors, 152
 SILAC, 200
 sinusoidal endothelial cells, 292
 siRNA, 54, 230, 380
Sleeping Beauty, 249
 SMT, 114
 SNP genotyping, 186
 SNPs, 375
 somatic, 79
 somatic cells, 317
 somatic genome editing, 447
 spacers, 276
 SpCas9, 360
 spinal muscle atrophy, 141
 SRCR, 140
 SSA, 169
 ssODN, 97, 101, 152
 ssODN donor, 106, 158
 ssODNs, 304
 ssRNA, 60
 staining solution, 347
 stereomicroscope, 88
 ST-HSCs, 301
 stoichiometry, 43
 streptavidin, 33
Streptococcus pyogenes, 23, 41, 337
 streptomycin, 25
 subretinal injection, 360
 Surveyor nuclease, 25
 swine research, 132
 systematic evolution of ligands by exponential enrichment (SELEX), 392
 systemic toxicity, 392

 T cells, 280
 T3 sequence, 44
 T7 Megascript, 87
 T7 sequence, 44
 T7/T3 integration, 47
 T7EI results, 187
 tagged IDLV, 28

 TALE, 55, 135, 277
 TALE domain, 7
 TALE domains, 8
 TALEN, 30, 34, 57, 80
 TALEN mRNAs, 74
 TALENs, 52, 61, 150, 165, 275, 316
 TALE-NT, 73
 T-cell antigen receptor, 111
 tdTomato (sgTom), 352
 TFRC, 60
 Th2 phenotype, 416
 Theiler's virus, 415
 therapeutic, 40
 TNF+zVAD, 217
 TNF- α (TNF), 215
 toll-like receptors (TLRs), 405
 toxic chemotherapy agents, 287
TP53, 340
TP53^{R167H}, 125
 tracrRNA, 72, 276
 transcription activator-like effector (TALE), 23
 transcription activator-like effector nucleases (TALENs), 7, 71
 transcriptome analyses, 71
 transcriptomic analysis, 371
 transgene, 316
 transgenic expression, 41
 transgenic mice, 316
 transgenic plants, 424
 transgenic technologies, 138
 transposable elements, 249
Tribolium castaneum, 74, 79
 TRIM5 α variants, 391
 tRNA, 52
 tumorigenesis, 316
 tyrosine aminotransferase (TAT), 29
 tyrosinemia, 255

 UDP normalized score (UNS), 48
 unique deletion patterns (UDP), 48
 untranslated regions (UTRs), 7, 76
 USPTO, 424

 vascular endothelium, 376
 VEGFA, 31
 vertebrate transgenesis, 254
 vesicular stomatitis virus, 26
 virion morphogenesis, 24
 VP16, 59

 Wang's models, 98
 WASCR-4, 31
 WASCR-5, 31
 Watson and Crick, 423
 Watson-Crick base pairs, 8, 23
 WGE, 153
 whole genomic sequencing (WGS), 24
 Wiskott-Aldrich Syndrome (WAS), 29
 WRPW domain, 59

472 **Index**

- X. tropicalis*, 87
- Xanthomonas*, 23
- Xenbase, 87
- Xenopus*, 85
- Xenopus laevis*, 84
- Xenopus* mRNAs, 85
- Xenopus tropicalis*, 84
- xenotransplantation, 143
- Xist RNA, 383
- X-SCID, 309
- Yang, 101
- Zajicek, 291
- zebrafish, 40, 61
- ZFN proteins, 394
- zinc-finger nucleases (ZFNs), 5, 22, 25, 52, 55, 56, 58, 61, 121, 150, 158, 165, 183, 275, 305, 316, 376
- zygotes, 115, 339
- zygotic injections, 173